420 with CNW — What the Future Holds for Hemp-Sourced

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
271
420 with CNW — What the Future Holds for Hemp-Sourced Cannabinoids

In the early 1970s, the federal government outlawed all cannabis cultivation, and failing to distinguish between hemp and its psychoactive cousin cannabis, declared it illegal to cultivate both cannabis and hemp. These policies held for decades, and while the illicit market continued supplying cannabis, hemp nearly faded into obscurity. In 2014, Congress passed a farm bill that allowed state agriculture departments and universities to grow hemp in pilot programs as long as their home states permitted it.

Four years later, the 2018 farm gill removed hemp from the list of controlled substances, allowing the cultivation, processing and sale of hemp and hemp derivatives. Just a few years later, America’s young hemp industry has blossomed, partly driven by the explosive demand for cannabinoids, CBD in particular.

Cannabinoids are chemical compounds produced by plants of the cannabis sativa species, which includes hemp and cannabis. Hemp has less than 0.3% THC, the main psychoactive compound in cannabis, hence hemp products will not intoxicate you.

Said to be filled with potent medicinal properties, CBD has made hemp extremely valuable. The CBD pace has advanced rather quickly, and some have called the industry a Wild West where hype has far outpaced science. Consequently, the FDA has warned several companies against marketing CBD products as over the counter medicines and raised concerns about adding CBD to ingestible products such as foods, beverages, and dietary supplements. Still, nearly every states has passed some form of hemp legislation and allows the use of hemp and its derivatives in a variety of consumer products, including ingestible products and pet products.

Other minor cannabinoids, including cannabigerol (“CBG”), delta-8 THC and cannabinol (“CBN”), have been subject to increasing attention. However, these minor cannabinoids are relatively unknown and make up a very small segment of the hemp industry. They still have plenty of regulatory hurdles to clear, let alone gaining the high level of market visibility that CBD has achieved within the past five years. Since these minor cannabinoids have barely been subject to scientific research and clinical studies, policymakers still do not understand them or what they can do.

In fact, we do not know a lot about most of the approximately 100 cannabinoids hemp produces. But based on how cannabidiol fared, we can assume that these cannabinoids will also go through a similar process. Increasing popularity will attract more sellers to the market, plenty of them unscrupulous. We may even see companies advertising these cannabinoids as miracle cures for certain diseases, much like some companies have done with CBD. However, the FDA has been quick to shut down such claims and offer guidance on CBD, and we can assume the federal agency will do the same with the larger hemp-sourced cannabinoid sector.

Sellers are constantly coming up with new CBD products, forcing federal and regulators to constantly redefine what is legal and what isn’t. Some states may allow cannabinoid-infused transdermal patches and CBD flower while others may not. Meanwhile, the FDA will continue to provide guidance on cannabinoids and how they can and cannot be used in the absence of a federal comprehensive regulatory structure.

At the moment, cannabis companies that are interested in different cannabinoids, such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), are working within the existing regulatory framework to manufacture premium products aimed at addressing the needs of their customers.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Red White & Bloom Brands Inc. (RWBYF) Stock Research Links

RWBYF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 111

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 63

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 137

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 56

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 186

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 45

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 52

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 139

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 134

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Whataburger Announces Leadership Transition with New CEO

Updated Category News Views 664

Whataburger Announces CEO Retirement and Leadership Transition Whataburger is making headlines with the news that Chief Executive Officer Ed Nelson will retire at the end of this year. This marks the conclusion of a significant chapter in the company’s journey. Over his two-decade tenure, Ed's leadership has profoundly impacted Whataburger's growth and expansion. Ed...

Continue Reading
Important Insights on BBAI Class Action and Shareholder Rights

Updated Category News Views 255

Understanding the Class Action Lawsuit for BigBear.ai Holdings, Inc. BigBear.ai Holdings, Inc. (NYSE: BBAI) is currently facing legal scrutiny as a class action lawsuit has been filed on behalf of shareholders who purchased the company's securities between specific periods of interest. Legal representatives are urging shareholders who believe they were adversely affected...

Continue Reading
Piramal Pharma Limited Delivers Strong Financial Growth in FY25

Updated Category News Views 480

Piramal Pharma Limited Announces Impressive Q2 and H1 FY25 Results Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a prominent player in the global pharmaceuticals and wellness industry, has reported its financial results for the Second Quarter (Q2) and Half Year (H1) of FY25, indicating a notable upward trend in its performance. Financial Highlights from Q2 FY25...

Continue Reading
Foresee Pharmaceuticals Launches Phase 2 Study for Mirivadelgat

Updated Category News Views 221

Foresee Pharmaceuticals Advances Treatment Options for PH-ILD Foresee Pharmaceuticals has recently marked a significant milestone by announcing the dosing of the first patient in its Phase 2 WINDWARD study. This critical study aims to assess the efficacy and safety of mirivadelgat, a novel oral medication designed for individuals suffering from pulmonary...

Continue Reading
Suki Secures $70 Million to Enhance AI Healthcare Solutions

Updated Category News Views 101

Suki's Impressive Funding Round Suki, an innovative healthcare startup, has successfully raised $70 million in its Series D funding round. This funding brings the company's total capital raised to an impressive $165 million. The news marks a significant step forward for Suki as it seeks to enhance its AI-assisted offerings aimed at reducing the administrative burdens...

Continue Reading